The Caov-3 cell line is a primary ovarian cancer cell line with epithelial morphology. These cells form tightly packed colonies in adherent culture. All-trans retinoic acid has been shown to suppress the growth of Caov-3 ovarian carcinoma cells in vitro. These cells express the NB/70K, CA-125, Ba-2, and Ca-1 tumor-associated antigens. The Caov-3 cells harbor a nonsense mutation in the p53 gene, and have multiple copies of the ovarian cancer oncogene PIK3CA. They are sensitive to vinblastine, cisplatin, and adriamycin. These cells fail to grow in soft agar but are tumorigenic when injected into immunocompromised mice.
This cell line was established from the primary tumor of a 54-year-old Caucasian female with adenocarcinoma of the ovary.
Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Buick RN et al. (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Research 45: 3668-3676 (PubMed ID: 4016745)
- Yaginuma Y et al. (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Research 52: 4196-4199 (PubMed ID: 1638534)
- Shayesteh L et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 21: 99 - 102 (PubMed ID: 9916799)
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at email@example.com. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For licensing requests for a commercial purpose: Contact Alexandra Buga, MS, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, firstname.lastname@example.org.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com.